The estimated Net Worth of Susan M Luscinski is at least $1.44 Milion dollars as of 18 October 2013. Susan Luscinski owns over 197,772 units of Harvard Bioscience stock worth over $1,436,754 and over the last 21 years Susan sold HBIO stock worth over $0.
Susan has made over 2 trades of the Harvard Bioscience stock since 2012, according to the Form 4 filled with the SEC. Most recently Susan exercised 197,772 units of HBIO stock worth $549,806 on 18 October 2013.
The largest trade Susan's ever made was exercising 197,772 units of Harvard Bioscience stock on 18 October 2013 worth over $549,806. On average, Susan trades about 17,516 units every 18 days since 2004. As of 18 October 2013 Susan still owns at least 507,687 units of Harvard Bioscience stock.
You can see the complete history of Susan Luscinski stock trades at the bottom of the page.
Susan's mailing address filed with the SEC is C/O HARVARD BIOSCIENCE, INC., 84 OCTOBER HILL ROAD, HOLLISTON, MA, 01746.
Over the last 21 years, insiders at Harvard Bioscience have traded over $10,145,146 worth of Harvard Bioscience stock and bought 754,658 units worth $2,380,232 . The most active insiders traders include Earl R Lewis, Bertrand Loy oraz David Green. On average, Harvard Bioscience executives and independent directors trade stock every 43 days with the average trade being worth of $182,054. The most recent stock trade was executed by James W Green on 13 June 2024, trading 10,000 units of HBIO stock currently worth $29,100.
harvard bioscience is a global developer, manufacturer and marketer of a broad range of specialized products, primarily apparatus and scientific instruments used to advance life science research at pharmaceutical and biotechnology companies, universities and government laboratories worldwide. we sell our products to thousands of researchers in over 100 countries through our full-line catalog (and various other specialty catalogs), our websites, and through distributors, including ge healthcare, thermo fisher scientific inc., and vwr. we have sales and manufacturing operations in the united states, the united kingdom, germany, and spain and sales facilities in france and canada.
Harvard Bioscience executives and other stock owners filed with the SEC include: